Recommendation ID

What is the effectiveness and cost effectiveness of immunotherapy in people with stage IIIA-N2 non-small-cell lung cancer following multimodality treatment including surgery?

Any explanatory notes
(if applicable)

Source guidance details

Comes from guidance
Lung cancer: diagnosis and management
Date issued
March 2019

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 28/03/2019